What is BioRestorative Therapies Profitability Rank?
BioRestorative Therapies has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
BioRestorative Therapies's Operating Margin % for the quarter that ended in Dec. 2023 was -16,952.63%. As of today, BioRestorative Therapies's Piotroski F-Score is 3.
Competitive Comparison of BioRestorative Therapies's Profitability Rank
For the Biotechnology subindustry, BioRestorative Therapies's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Profitability Rank distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's Profitability Rank falls into.
BioRestorative Therapies Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
BioRestorative Therapies has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
BioRestorative Therapies's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
BioRestorative Therapies has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Warning Sign:
BioRestorative Therapies Inc operating margin has been in a 5-year decline. The average rate of decline per year is -23.8%.
4. Consistency of the profitability
5. Predictability Rank
BioRestorative Therapies (BioRestorative Therapies) Business Description
Traded in Other Exchanges
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Executives
| Dale Broadrick |
10 percent owner |
3003 BRICK CHURCH PIKE, NASHVILLE TN 37207 |
| Lance Alstodt |
director, 10 percent owner, officer: President, CEO, COB |
BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747 |
| Francisco Silva |
director, 10 percent owner, officer: VP of Research and Development |
STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458 |
| Robert Eugene Kristal |
officer: Chief Financial Officer |
4719 COLE AVENUE, DALLAS TX 75205 |
| Patrick F. Williams |
director |
C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588 |
| David A Rosa |
director |
10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343 |
| Nickolay V. Kukekov |
director |
4524 WESTWAY AVE, DALLAS TX 75205 |
| Mark Weinreb |
director, 10 percent owner, officer: CEO and Chairman of the Board |
STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458 |
| Paul Jude Tonna |
director |
69 CHICHESTER ROAD, HUNTINGTON NY 11743 |
| A. Jeffrey Radov |
director |
8 WALWORTH AVENUE, SCARSDALE NY 10583 |
| Robert Paccasassi |
officer: VP, Quality and Compliance |
C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747 |
| Robert B Catell |
director |
62 OSBORNE ROAD, GARDEN CITY NY 11530 |
| Adam D. Bergstein |
officer: SVP, Planning and Business Dev |
167 HAZEL AVENUE, GLENCOE IL 60022 |
| John M Desmarais |
director |
230 PARK AVENUE, NEW YORK NY 10169 |
| Westbury Trust |
10 percent owner |
VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BRTX has been successfully added to your